2025
Pilot study evaluating duplex sequencing of urinary DNA as a biomarker for recurrence in non-muscle invasive bladder cancer.
Ghali F, Blaha O, Lam H, Kennedy S, Wright J. Pilot study evaluating duplex sequencing of urinary DNA as a biomarker for recurrence in non-muscle invasive bladder cancer. Journal Of Clinical Oncology 2025, 43: 865-865. DOI: 10.1200/jco.2025.43.5_suppl.865.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerInvasive bladder cancerVariant allele fractionUrinary DNAIntravesical therapyBladder cancerPathogenic variantsTransurethral resection of bladder tumorMedian time to recurrenceResection of bladder tumorNext-generation sequencingDetection of recurrenceTime to recurrenceTime to relapseRecurrence of tumorBiomarkers of recurrencePilot studyTransurethral resectionBladder tumorsMedian ageRecurrenceAllele fractionUrine samplesTumorBiomarkers
2024
Strategically Staged Tumor Ablation and Inflammation Suppression Using Shell‐Core Nanoparticles to Eradicate Bladder Tumors and Prevent Recurrence
Xu Y, Zhang R, Zhu J, Guo Z, Jin D, Qian L, Yang Y, Chen H. Strategically Staged Tumor Ablation and Inflammation Suppression Using Shell‐Core Nanoparticles to Eradicate Bladder Tumors and Prevent Recurrence. Advanced Functional Materials 2024, 34 DOI: 10.1002/adfm.202402078.Peer-Reviewed Original ResearchPrevent tumor recurrenceBladder tumorsTumor recurrenceTumor ablationPreventing bladder tumor recurrenceRat bladder tumor modelBladder tumor modelBladder tumor recurrenceInflammation suppressionCancer-related inflammationRelease of nitric oxideAnti-inflammatory effectsAcidic tumor environmentTumor environmentTumor modelPrevent recurrenceReduce inflammationTumorRecurrenceInflammationReactive oxygen speciesNitric oxideIn vitroAbstract NanomedicineAnti-tumor
2023
International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance
Tan W, Contieri R, Buffi N, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat A. International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance. Journal Of Urology 2023, 210: 763-770. PMID: 37535836, DOI: 10.1097/ju.0000000000003639.Peer-Reviewed Original ResearchTransurethral resection of bladder tumorResection of bladder tumorNonmuscle-invasive bladder cancerTransurethral resectionBladder tumorsActive surveillanceBladder cancerScoring systemNonmuscle-invasive bladder cancer patientsAbsence of gross hematuriaMultivariate Cox proportional hazards analysisRisk factorsNonmuscle-invasive bladder tumorsNegative urinary cytologyCox proportional hazards analysisMedian Follow-UpMultivariate Cox regressionBladder cancer patientsProportional hazards analysisUrinary cytologyGross hematuriaT stageLandmark time pointsFollow-upCox regressionAssociation of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome in Bladder Cancer
Murakami K, Furuya H, Hokutan K, Goodison S, Pagano I, Chen R, Shen C, Chan M, Ng C, Kobayashi T, Ogawa O, Miyake M, Thornquist M, Shimizu Y, Hayashi K, Wang Z, Yu H, Rosser C. Association of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome in Bladder Cancer. International Journal Of Molecular Sciences 2023, 24: 4943. PMID: 36902377, PMCID: PMC10003630, DOI: 10.3390/ijms24054943.Peer-Reviewed Original ResearchConceptsPlasminogen activator inhibitor-1Bladder cancerSingle nucleotide polymorphismsMutational statusWorse recurrence-free survivalUntranslated region (UTR) single nucleotide polymorphismRecurrence-free survivalBladder cancer developmentHuman bladder tumorsAssociation of SNPsCommon cancer typesActivator inhibitor-1Anti-apoptotic effectsOverall survivalDisease recurrenceClinical outcomesOverall incidenceBladder tumorsCaucasian patientsIndependent cohortCancer typesCancer developmentCancerInhibitor-1Cellular proliferation
2022
A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E
Tan W, Bello A, Alvarez C, Guerrero-Ramos F, González-Padilla D, Nzeh C, de la Morena J, de Torres I, Hendricksen K, Goizueta F, Del Álamo J, Chiancone F, Fedelini P, Poggio M, Porpiglia F, Rodríguez V, Torres J, Wilby D, Robinson R, Sousa-Escandón A, Mata J, Moreno J, Molina F, Semino M, Stemberger A, Escudero J, Redorta J, Tan W. A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E. Bladder Cancer 2022, 8: 379-393. PMID: 38994184, PMCID: PMC11181696, DOI: 10.3233/blc-220026.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerTransurethral resection of bladder tumorRecurrence-free survivalProgression-free survivalInvasive bladder cancerMitomycin CBCG-naiveBladder cancerAdverse eventsTreated with intravesical bacillus Calmette-GuerinTreatment of non-muscle invasive bladder cancerIntravesical bacillus Calmette-GuerinResection of bladder tumorTreating non-muscle invasive bladder cancerFavorable adverse event profileAdverse event profileBacillus Calmette-GuerinMinor adverse eventsMulti-institutional studyBCG failurePapillary diseaseTransurethral resectionBladder tumorsConsecutive patientsMedian age
2021
RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics
Bekele RT, Samant AS, Nassar AH, So J, Garcia EP, Curran CR, Hwang JH, Mayhew DL, Nag A, Thorner AR, Börcsök J, Sztupinszki Z, Pan CX, Bellmunt J, Kwiatkowski DJ, Sonpavde GP, Van Allen EM, Mouw KW. RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. Journal Of Clinical Investigation 2021, 131 PMID: 34554931, PMCID: PMC8592548, DOI: 10.1172/jci147849.Peer-Reviewed Original ResearchConceptsBladder tumorsUrothelial tumorsTherapeutic strategiesNovel therapeutic strategiesRational therapeutic strategiesPatient-derived modelsRaf/MEK/ERKClinical outcomesMEK/ERKTreatment optionsBladder cancerHeterogeneous diseaseMEK inhibitionTumorsUnique subsetFocal amplificationRAF inhibitorsCell linesRAF1Gene expression patternsActivationExpression patternsSignalingSubsetRaf1 activityDiagnostic value of a comprehensive, urothelial carcinoma–specific next‐generation sequencing panel in urine cytology and bladder tumor specimens
Sun T, Hutchinson L, Tomaszewicz K, Caporelli M, Meng X, McCauley K, Fischer AH, Cosar EF, Cornejo KM. Diagnostic value of a comprehensive, urothelial carcinoma–specific next‐generation sequencing panel in urine cytology and bladder tumor specimens. Cancer Cytopathology 2021, 129: 537-547. PMID: 33539671, DOI: 10.1002/cncy.22410.Peer-Reviewed Original ResearchConceptsLow-grade urothelial carcinomaHigh-grade urothelial carcinomaUrine cytology specimensUrothelial carcinomaCytology specimensDiagnostic utilityUrine cytologyNGS panelNext-generation sequencing panelHigh-grade tumorsNext-generation sequencingBiopsy/resectionPossible diagnostic utilityTumor biopsy/resectionCancer Genome AtlasBladder tumorsResection specimensSurgical specimensThinPrep cytologySequencing panelHGUC casesDiagnostic valueCarcinomaCytologyPilot study
2019
Prostatic Artery Embolization in Nonindex Benign Prostatic Hyperplasia Patients: Single-center Outcomes for Urinary Retention and Gross Prostatic Hematuria
Ayyagari R, Powell T, Staib L, Chapiro J, Perez-Lozada JC, Bhatia S, Chai T, Schoenberger S, Devito R. Prostatic Artery Embolization in Nonindex Benign Prostatic Hyperplasia Patients: Single-center Outcomes for Urinary Retention and Gross Prostatic Hematuria. Urology 2019, 136: 212-217. PMID: 31734349, DOI: 10.1016/j.urology.2019.11.003.Peer-Reviewed Original ResearchConceptsProstatic artery embolizationBenign prostatic hyperplasia patientsProstatic hyperplasia patientsInternational Prostate Symptom ScoreProstatic hematuriaHyperplasia patientsUrinary retentionArtery embolizationPostvoid residualHematuria patientsSingle-center outcomesUrinary retention patientsClavien-Dindo classificationProstate Symptom ScoreQuality of lifeTransfusion rateGross hematuriaSH patientsUrinary infectionBladder irrigationGH patientsSymptom scoresUR patientsBladder tumorsDurable treatmentGlycoprotein-130 expression is associated with aggressive bladder cancer and is a potential therapeutic target
Martin DT, Shen H, Steinbach-Rankins JM, Zhu X, Johnson KK, Syed J, Saltzman WM, Weiss RM. Glycoprotein-130 expression is associated with aggressive bladder cancer and is a potential therapeutic target. Molecular Cancer Therapeutics 2019, 18: molcanther.1079.2017. PMID: 30381445, PMCID: PMC6363894, DOI: 10.1158/1535-7163.mct-17-1079.Peer-Reviewed Original ResearchConceptsBladder cancer cell linesBladder tumorsBladder cancerCancer cell linesHigh-grade bladder cancer cell linesCancer xenograft mouse modelBladder cancer growthAggressive bladder cancerPotential therapeutic targetHuman bladder tumorsXenograft mouse modelBladder cancer progressionCell linesBladder tumor cellsCurative potentialOptimal treatmentTumor gradePatient outcomesReduced cell migrationTumor volumeTumor categoryMouse modelTherapeutic targetTumor aggressivenessCancer growth
2018
Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR
Lee E, Collazo-Lorduy A, Castillo-Martin M, Gong Y, Wang L, Oh W, Galsky M, Cordon-Cardo C, Zhu J. Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. Oncogene 2018, 37: 5858-5872. PMID: 29970902, PMCID: PMC6212417, DOI: 10.1038/s41388-018-0367-0.Peer-Reviewed Original ResearchConceptsMiR-106b-5pMiRNA expression signaturesBladder cancerMiR-532MiR-106Resistance to cisplatin-based chemotherapyPrognostic biomarkerMuscle-invasive bladder cancerAssociated with better survivalCisplatin-based chemotherapyHeterogeneous clinical outcomesMiRNA expressionMiRNAsPersonalized treatment optionsBladder tumorsPrognostic groupsBasal subtypeBetter survivalPrognostic markerTumor typesClinical outcomesTreatment optionsTumor progressionCancer Genome AtlasMiRNA activity
2016
What factors are associated with unplanned return following transurethral resection of bladder tumor? An analysis of a large single institution’s experience
Ghali F, Moses R, Raffin E, Hyams E. What factors are associated with unplanned return following transurethral resection of bladder tumor? An analysis of a large single institution’s experience. Scandinavian Journal Of Urology 2016, 50: 370-373. PMID: 27438524, DOI: 10.1080/21681805.2016.1201856.Peer-Reviewed Original ResearchConceptsAspirin therapyPreoperative antibioticsGross hematuriaMultivariable analysisTransurethral resectionTumor sizeBladder tumorsOperating roomFemale genderLargest single-institution experienceSingle institution experienceDay of surgeryFoley catheter placementLength of staySingle academic institutionHospital dischargeRetrospective reviewUnplanned returnCatheter placementFoley catheterizationInstitution experienceMean ageFoley placementDistance of residenceCommon cause
2015
Blocking Glycoprotein‐130 Pathway Decreases Bladder Cancer Growth
Martin D, Steinbach J, Saltzman W, Weiss R. Blocking Glycoprotein‐130 Pathway Decreases Bladder Cancer Growth. The FASEB Journal 2015, 29 DOI: 10.1096/fasebj.29.1_supplement.889.11.Peer-Reviewed Original ResearchBacillus Calmette-GuerinExpression of gp130Bladder cancer cellsBladder cancerCancer specimensNon-muscle invasive bladder cancerCancer cellsEffective adjuvant agentInvasive bladder cancerWeeks of treatmentBladder cancer tissue microarrayBladder cancer growthComprehensive cancer centerBladder cancer specimensCancer tissue microarrayHuman bladder cancerAdjuvant agentBladder tumorsCancer CenterCytokeratin 20Signal transduction pathwaysCalmette-GuerinTumor gradeTissue microarrayCarcinoma markers
2012
The impact of regional anesthesia on bladder cancer outcomes.
RiChard J, Lipsky M, Whalen M, Motamedinia P, Finkelstein J, Hruby G, DeCastro G, Curry S, Benson M, McKiernan J. The impact of regional anesthesia on bladder cancer outcomes. Journal Of Clinical Oncology 2012, 30: e15021-e15021. DOI: 10.1200/jco.2012.30.15_suppl.e15021.Peer-Reviewed Original ResearchRadical cystectomyGeneral anesthesiaBladder cancer outcomesCancer outcomesPost-operative opioid useMultivariate logistic regressionImpact of RAAnesthesia typeAnesthesia modalityIncomplete resectionOpioid usePatient comorbiditiesCarcinoma recurrenceTransurethral resectionTumor characteristicsClinical stageBladder tumorsSurgery showOperative characteristicsCancer recurrenceProcedure typeRegional anesthesiaTURBTOnly predictorPatients
2010
Novel ZEB1 expression in bladder tumorigenesis
Kenney PA, Wszolek MF, Rieger‐Christ K, Neto BS, Gould JJ, Harty NJ, Mosquera JM, Zeheb R, Loda M, Darling DS, Libertino JA, Summerhayes IC. Novel ZEB1 expression in bladder tumorigenesis. BJU International 2010, 107: 656-663. PMID: 20735391, DOI: 10.1111/j.1464-410x.2010.09489.x.Peer-Reviewed Original ResearchConceptsEpithelial-mesenchymal transitionTransitional cell carcinomaZEB1 expressionNuclear ZEB1 expressionTissue microarrayBladder tumorsTumor progressionGrade I/IIBladder tumorigenesisMuscle-invasive UCBCancer-specific survivalGrade III tumorsNormal bladder mucosaExpression levelsExpression of ZEB1Underlying cellular changesCell linesBladder cell linesUM-UC-3Bladder tumor progressionProtein expression levelsBladder carcinoma cell lineInvasive UCBWestern blot analysisNodal involvement
2009
Ureteral Fibrin Sealant Injection of the Distal Ureter During Laparoscopic Nephroureterectomy—A Novel and Simple Modification of the Pluck Technique
Mueller T, DaJusta D, Yoon D, Kim I, Ankem M. Ureteral Fibrin Sealant Injection of the Distal Ureter During Laparoscopic Nephroureterectomy—A Novel and Simple Modification of the Pluck Technique. Urology 2009, 75: 187-192. PMID: 19913884, DOI: 10.1016/j.urology.2009.06.101.Peer-Reviewed Original ResearchConceptsFibrin sealant injectionDistal ureterLaparoscopic nephroureterectomyPostoperative dayUreteral orificeUpper tract transitional cell carcinomaTract transitional cell carcinomaAverage operative timeTransitional cell carcinomaCollins knifeIntravesical recurrenceMean cancerNormal cystogramPluck techniqueUreteral blockageTumor spillageMinor complicationsBlood lossMedian ageOperative timeFoley catheterUreteral obstructionBladder tumorsCell carcinomaSpecimen margins
1999
INDUCIBLE NITRIC OXIDE SYNTHASE WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER
SWANA H, SMITH S, PERROTTA P, SAITO N, WHEELER M, WEISS R. INDUCIBLE NITRIC OXIDE SYNTHASE WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER. Journal Of Urology 1999, 161: 630-634. PMID: 9915473, DOI: 10.1016/s0022-5347(01)61985-2.Peer-Reviewed Original ResearchConceptsTransitional cell carcinomaNitric oxide synthaseInducible nitric oxide synthaseReverse transcriptase-polymerase chain reactionBladder tissueCell carcinomaInflammatory cellsNOS activityOxide synthaseNitric oxideTumor cellsGrades of TCCDistribution of iNOSImmunoreactive iNOS proteinHuman bladder tumorsTranscriptase-polymerase chain reactionIndividual tumor cellsControl bladder tissueCytostatic mediatorsINOS antibodyTumor immunoreactivityWestern blot analysisBladder tumorsTumor gradeImmune stimulationINDUCIBLE NITRIC OXIDE SYNTHASE WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER
SWANA H, SMITH S, PERROTTA P, SAITO N, WHEELER M, WEISS R. INDUCIBLE NITRIC OXIDE SYNTHASE WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER. Journal Of Urology 1999, 161: 630-634.. DOI: 10.1097/00005392-199902000-00090.Peer-Reviewed Original ResearchTransitional cell carcinomaNitric oxide synthaseInducible nitric oxide synthaseReverse transcriptase-polymerase chain reactionBladder tissueCell carcinomaInflammatory cellsNOS activityOxide synthaseAbstract Purpose Nitric oxideNitric oxideTumor cellsGrades of TCCDistribution of iNOSImmunoreactive iNOS proteinPurpose Nitric oxideHuman bladder tumorsTranscriptase-polymerase chain reactionIndividual tumor cellsControl bladder tissueCytostatic mediatorsINOS antibodyTumor immunoreactivityWestern blot analysisBladder tumors
1998
Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes.
Lee D, Yang S, Hong S, Chung B, Kim I. Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. Clinical Cancer Research 1998, 4: 535-8. PMID: 9533519.Peer-Reviewed Original ResearchConceptsTransitional cell carcinomaBladder transitional cell carcinomaBladder washesCell carcinomaCytological diagnosisTelomerase activityGrade 1 transitional cell carcinomaCancer tissuesNormal tissuesHuman bladder cancer tissuesBladder wash samplesPositive telomerase activityFinal pathological diagnosisLow-grade tumorsBladder cancer tissuesTelomeric repeat amplificationPositive cytologyTransurethral resectionBladder tumorsBladder cancerPathological diagnosisWash samplesCytological specimensPatientsPotential marker
1997
Ureteral Carcinoma in Situ at Radical Cystectomy: Does the Margin Matter?
Silver D, Stroumbakis N, Russo P, Fair W, Herr H. Ureteral Carcinoma in Situ at Radical Cystectomy: Does the Margin Matter? Journal Of Urology 1997, 158: 768-771. DOI: 10.1016/s0022-5347(01)64312-x.Peer-Reviewed Original ResearchConceptsUreteral carcinomaRadical cystectomyCarcinoma recurrencePositive cytologyMargin statusBladder cancerBacillus Calmette-Guerin treatmentRenal pelvis/ureterConsecutive radical cystectomiesUpper tract carcinomaUpper tract recurrenceCancer-specific survivalMetastatic bladder cancerPositive urinary cytologyFrozen section examinationLack of morbidityBladder tumor stageExpectant managementTract recurrenceMedian followupUreteral resectionSpecific survivalNegative marginsBladder tumorsTumor stageUreteral Carcinoma in Situ at Radical Cystectomy
Silver D, Stroumbakis N, Russo P, Fair W, Herr H. Ureteral Carcinoma in Situ at Radical Cystectomy. Journal Of Urology 1997, 158: 768-771.. PMID: 9258077, DOI: 10.1097/00005392-199709000-00020.Peer-Reviewed Original ResearchConceptsUreteral carcinomaRadical cystectomyCarcinoma recurrencePositive cytologyMargin statusBladder cancerBacillus Calmette-Guerin treatmentRenal pelvis/ureterConsecutive radical cystectomiesUpper tract carcinomaUpper tract recurrenceCancer-specific survivalMetastatic bladder cancerPositive urinary cytologyFrozen section examinationLack of morbidityBladder tumor stageUreteral marginsExpectant managementTract recurrenceMedian followupSpecific survivalUreteral resectionNegative marginsBladder tumors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply